Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies

ConclusionAlthough the objective responses to eribulin were uncommon, disease control was observed in the majority of patients.

Source: Head and Neck - December 28, 2017 Category: ENT & OMF Authors: Cristina P. Rodriguez, Renato G. Martins, Christina Baik, Laura Q. Chow, Rafael Santana ‐Davila, Bernardo H. Goulart, Sylvia Lee, Keith D. Eaton Tags: ORIGINAL ARTICLE Source Type: research